Rankia Colombia
Acceder
¿Nos visitas desde USA? Entra a tu página Rankia.us.

Foro de Bolsa > Farmas USA

ACAD Nota de BAML: Physician survey signals continued growth for Nuplazid

<< Volver al mensaje 'ACAD Nota de BAML: Physician survey signals continued growth for Nuplazid'

mugiwara
#113461

Re: Farmas USA

ACAD

Nota de BAML:

Physician survey signals continued growth for Nuplazid

Our estimates for future Nuplazid sales 
We currently assume $277mn (+24% y/y) for Nuplazid PDP sales in 2019 ramping up to 
$732mn in 2026. We view upcoming data from schizophrenia (ph 3 ENHANCE readout in 
mid-2019) and dementia-related psychosis (ph 3 HARMONY interim readout in 2H19 
and full data in 2020) could provide additional source for future revenue growth. We 
maintain our Buy rating on Acadia Pharmaceuticals (ACAD) with a $27 PO. 

Todo el tocho completo aquí:

https://www.investorvillage.com/smbd.asp?mb=523&mn=14799&pt=msg&mid=19130402

<< Volver al mensaje 'ACAD Nota de BAML: Physician survey signals continued growth for Nuplazid'
Guardado por 1 usuario

¿Cuál es mi broker ideal?

Brokers destacados